+91 80 2808 2808
Biocon  /  Products  /  Key Therapeutic Areas  /  Diabetes



Diabetes is accelerating at an alarming rate globally. Today, over 475 million people across all age groups and social classes, live with the chronic condition. What is even more worrying is the fact that this mostly goes undetected until it reaches life-threatening proportions.

The constant monitoring, apart from the actual treatment, makes diabetes management an expensive process. As a credible, global player in the area of diabetes, Biocon is committed to making therapies for diabetes management increasingly affordable and accessible across the globe.



Recombinant human Insulin

Insugen®, the world’s first recombinant human insulin (rh-Insulin) developed on a proprietary Pichia pastoris platform, was introduced in India in 2004.

Biocon Biologics has provided over 2.75 billion doses of rh-Insulin worldwide, so far.

Biocon Biologics is developing rh-Insulin for the U.S. market.

Biocon’s biosimilar Insulin 70/30 demonstrates equivalence with U.S.-licensed HUMULIN® 70/30 formulation in healthy subjects: Study.

PDF Download

Biocon Biologics is expanding insulin access by offering rh-Insulin at less than 10 US cents / day to governments in LMICs as a part of its ‘Mission 10 Cents’ program

A Century of Insulins and Biocon Biologics



Insulin Glargine

Biocon launched Insulin Glargine under the brand name Basalog® in 2009, providing an advanced, affordable, long-acting insulin analog to diabetes patients in India.

Biocon Biologics’ biosimilar Insulin Glargine was the first biosimilar from India to be approved & launched in Japan.

Biocon Biologics’ biosimilar Insulin Glargine received approval and was commercialized in U.S. by its partner Viatris in 2020.

Biocon Biologics’ biosimilar Insulin Glargine became the world’s first biosimilar to receive interchangeable approval from U.S. FDA.

Committed to Making Insulins Available & Accessible


Insulin Aspart

Biocon Biologics’ biosimilar Insulin Aspart has received regulatory approvals in developed markets like EU & Canada and emerging markets like Malaysia.



Novel Biologics

Insulin Tregopil

Insulin Tregopil, a first-in-class oral insulin molecule being developed by Biocon, is one of the most advanced programs in the global oral insulin space. It has completed a Phase II study in Type 2 diabetes patients in India.

Insulin Tregopil is undergoing a multiple ascending dose study in Type 1 diabetes patients in Germany, in partnership with the U.S.-based JDRF, a leading global organisation funding Type 1 diabetes research and advocacy worldwide.


Biocon offers a strong portfolio of generic APIs for diabetes that include:

  • Vildagliptin
  • Linagliptin
  • Sitagliptin (various salts)
  • Dapagliflozin (different solvate forms)
  • Empagliflozin
  • Repaglinide
  • Liraglutide
  • Semaglutide

The leader in Insulins

1st company globally to develop rh-insulin using a proprietary yeast platform based on Pichia pastoris.

1st company from India to get approval for and commercialise biosimilar Insulin Glargine in Japan.

1st company from India to commercialise biosimilar Insulin Glargine in Australia through the Pharmaceutical Benefits Scheme (PBS).

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>